$NWBO DCVAx is here to stay ! Important point : One crucial point: you cannot directly rank a DCVax-L against a V940 as though they’re competing drugs, because they’re treating different cancers and measuring different endpoints. GBM is amongst the hardest cancers to treat and NWBO aced it meaning the road ahead may be a shoe-in to treat much less agressive cancers. The mRNA can encode up to 34 tumor-specific neoantigens, intended to stimulate T cells against cancer cells carrying those mutations whilst DCVAX T-cell receptor studies found expansion of HUNDREDS of different T-cell clones, reaching as many as ~1,200 distinct clones in some samples after treatment. Each clone recognizes a distinct tumor target. That’s one of the most interesting fact : V940 tries to identify the best m
在 X 查看 ↗